JP2007510656A5 - - Google Patents

Download PDF

Info

Publication number
JP2007510656A5
JP2007510656A5 JP2006538425A JP2006538425A JP2007510656A5 JP 2007510656 A5 JP2007510656 A5 JP 2007510656A5 JP 2006538425 A JP2006538425 A JP 2006538425A JP 2006538425 A JP2006538425 A JP 2006538425A JP 2007510656 A5 JP2007510656 A5 JP 2007510656A5
Authority
JP
Japan
Prior art keywords
composition
trospium
release
trospium chloride
daily administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006538425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510656A (ja
JP5610663B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/036394 external-priority patent/WO2005046684A1/en
Publication of JP2007510656A publication Critical patent/JP2007510656A/ja
Publication of JP2007510656A5 publication Critical patent/JP2007510656A5/ja
Application granted granted Critical
Publication of JP5610663B2 publication Critical patent/JP5610663B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

JP2006538425A 2003-11-04 2004-11-04 トロスピウムの１日１回剤形 Expired - Fee Related JP5610663B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51719803P 2003-11-04 2003-11-04
US60/517,198 2003-11-04
US52396803P 2003-11-21 2003-11-21
US60/523,968 2003-11-21
PCT/US2004/036394 WO2005046684A1 (en) 2003-11-04 2004-11-04 Once daily dosage forms of trospium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012104795A Division JP5783489B2 (ja) 2003-11-04 2012-05-01 トロスピウムの１日１回剤形

Publications (3)

Publication Number Publication Date
JP2007510656A JP2007510656A (ja) 2007-04-26
JP2007510656A5 true JP2007510656A5 (enExample) 2014-08-28
JP5610663B2 JP5610663B2 (ja) 2014-10-22

Family

ID=34594857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006538425A Expired - Fee Related JP5610663B2 (ja) 2003-11-04 2004-11-04 トロスピウムの１日１回剤形
JP2012104795A Expired - Fee Related JP5783489B2 (ja) 2003-11-04 2012-05-01 トロスピウムの１日１回剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012104795A Expired - Fee Related JP5783489B2 (ja) 2003-11-04 2012-05-01 トロスピウムの１日１回剤形

Country Status (11)

Country Link
US (12) US7410978B2 (enExample)
EP (2) EP1680110B1 (enExample)
JP (2) JP5610663B2 (enExample)
AT (1) ATE493981T1 (enExample)
AU (1) AU2004289223B2 (enExample)
CA (1) CA2537103C (enExample)
DE (1) DE602004030931D1 (enExample)
DK (1) DK2210605T3 (enExample)
ES (1) ES2359375T3 (enExample)
PT (1) PT2210605T (enExample)
WO (1) WO2005046684A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004289222B2 (en) 2003-11-04 2010-01-21 Supernus Pharmaceuticals Inc. Compositions of quaternary ammonium containing bioavailability enhancers
US7410978B2 (en) * 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
US20070134315A1 (en) * 2005-12-08 2007-06-14 Viera Michael L Orally administrable extended release pellet and tablet formulations of a highly water soluble compound
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
SI1880718T1 (sl) * 2006-07-10 2011-11-30 Pfleger R Chem Fab Farmacevtski pripravki za oralno dajanje z nadzorovanim sproščanjem zdravila v majhne intestinke kolone in postopek njihove priprave
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP1973528B1 (en) 2006-11-17 2012-11-07 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
WO2008070670A2 (en) * 2006-12-04 2008-06-12 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
WO2009130712A2 (en) * 2008-04-22 2009-10-29 Lupin Limited Controlled release pharmaceutical compositions of trospium
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PL3061821T3 (pl) * 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2011159824A1 (en) * 2010-06-16 2011-12-22 Allergan, Inc. Composition and method for treating overactive bladder
JP6042330B2 (ja) 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時／遅延放出送達システム
BR112013028505A2 (pt) 2011-05-10 2017-01-10 Theravida Inc combinações de tróspio e estimulantes salivares para o tratamento de bexiga hiperativa
BR112013028755A2 (pt) 2011-05-10 2017-01-31 Theravida Inc combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa
CA2852042C (en) 2012-03-02 2018-05-01 Rhodes Pharmaceuticals L.P. Tamper resistant immediate release formulations
US9457008B2 (en) * 2012-03-23 2016-10-04 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Joint product comprising synephrine and topiramate
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
MX358211B (es) * 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
US10751287B2 (en) * 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CN104739808B (zh) * 2015-02-13 2017-09-22 舒泰神（北京）生物制药股份有限公司 一种曲司氯铵双释放胶囊及其制备方法
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis
JP7096441B2 (ja) 2018-09-28 2022-07-05 カルナ セラピューティックス，インコーポレイテッド ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US518777A (en) * 1894-04-24 Bicycle
US2899357A (en) * 1959-08-11 Oral pharmaceutical composition for
US652837A (en) * 1899-11-17 1900-07-03 Daniel Mcnamara Wheel for vehicles.
US2095282A (en) 1935-03-15 1937-10-12 Standard Oil Co Capillary viscometer
US2956926A (en) 1958-09-23 1960-10-18 American Cyanamid Co Coated citric acid particles
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
DE1194422B (de) * 1963-03-05 1965-06-10 Robert Pfleger Chem Fab Dr Verfahren zur Herstellung von Azoniaspironortropanderivaten
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
DE3237575A1 (de) 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
ATE43789T1 (de) 1985-02-23 1989-06-15 Asta Pharma Ag Kombination von flupirtin und anticholinergisch wirkenden spasmolytika.
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JP2528652B2 (ja) 1987-03-30 1996-08-28 エスエス製薬株式会社 持効性セフラジン製剤
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5279660A (en) 1988-05-24 1994-01-18 Berol Nobel Stenungsund Ab Use of viscosity-adjusting agent to counteract viscosity decrease upon temperature increase of a water-based system
US5520932A (en) 1988-06-24 1996-05-28 The Upjohn Company Fine-milled colestipol hydrochloride
US4970081A (en) * 1989-01-03 1990-11-13 Sterling Drug Inc. Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5372823A (en) 1989-03-16 1994-12-13 Bristol-Myers Squibb Company Direct compression cholestyramine tablet and solvent-free coating thereof
US5179660A (en) * 1989-05-15 1993-01-12 International Business Machines Incorporated System for reducing communications overhead in distributed database transactions by serializing in order related requests into single transmission message and receiving transmission response
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
EP0481038B1 (en) * 1990-04-16 2002-10-02 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5686094A (en) 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
US5095282A (en) * 1990-08-23 1992-03-10 Nvision, Inc. Differential amplifier apparatus
US5203203A (en) * 1990-10-10 1993-04-20 Bryan William L Viscometer for in situ monitoring
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
DK0606366T3 (da) * 1991-09-26 2003-10-06 Us Gov Health & Human Serv Substituerede phenseriner og phenylcarbamater af (-)-eserolin, (-)-N1-noreserolin og (-)-N1-benzylnoreserolin som specifikke inhibitorer af acetylcholinesterase
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
EP0627218B1 (en) * 1992-02-18 2001-12-19 Nippon Shinyaku Company, Limited Process for producing fast soluble tablets and fast soluble tablets comprising xylitol
US5405648A (en) 1993-05-10 1995-04-11 Hermann; Paul F. Coating particulate material with a polymer film
DE69428707T2 (de) * 1993-08-20 2002-07-11 Nippon Shinyaku Co., Ltd. Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
CA2164344C (en) * 1993-08-30 2004-06-29 Stanley Lech Tablet coating based on a melt-spun mixture of a saccharide and a polymer
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5520832A (en) * 1994-10-28 1996-05-28 Exxon Research And Engineering Company Tractor hydraulic fluid with wide temperature range (Law180)
JPH08157392A (ja) 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
US5582838A (en) 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
FI98343C (fi) * 1995-03-21 1997-06-10 Orion Yhtymae Oy Peroraalinen formulaatio
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US5779661A (en) * 1995-12-11 1998-07-14 Physion, S.R.L. Method of treating dysfunctional bladder syndromes by electromotive drug administration
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
JP3929522B2 (ja) * 1996-03-14 2007-06-13 塩野義製薬株式会社 難水溶性薬物の徐放性製剤
US6156340A (en) * 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
JPH09315969A (ja) 1996-05-24 1997-12-09 Taiyo Yakuhin Kogyo Kk イブジラスト含有徐放性医薬品組成物及びその製造方法
US6063808A (en) 1996-07-01 2000-05-16 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolate
US5959196A (en) * 1996-09-10 1999-09-28 Norcross Corporation In-line viscometer
US20010003588A1 (en) 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
ES2125696T3 (es) * 1996-11-27 1999-03-01 Pfleger R Chem Fab Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
US5973389A (en) * 1997-04-22 1999-10-26 International Business Machines Corporation Semiconductor chip carrier assembly
US6141624A (en) * 1997-05-13 2000-10-31 International Remote Imaging Systems Fluid sample for analysis controlled by total fluid volume and by total particle counts
ES2203963T3 (es) * 1997-05-30 2004-04-16 Osmotica Corp. Dispositivo osmotico multicapa.
US6141625A (en) 1997-06-09 2000-10-31 Dickey-John Corporation Viscometer module with crystal resonator-type sensor
DE19724696A1 (de) 1997-06-12 1998-12-24 Hexal Ag Pharmazeutische Zubereitung mit drei Pelletarten
US6197331B1 (en) 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
CO5070568A1 (es) * 1998-05-22 2001-08-28 Eurand Internatrional Spa Proceso de aplicacion de capas y aparato para efectuarlo
JP2000103732A (ja) * 1998-07-28 2000-04-11 Tanabe Seiyaku Co Ltd 腸内適所放出型製剤
KR100501022B1 (ko) 1998-07-28 2005-07-18 다나베 세이야꾸 가부시키가이샤 장내 적소 방출형 제제
SI1039882T1 (sl) 1998-08-27 2011-01-31 Pfizer Health Ab Terapevtska formulacija za dajanje tolterodina s kontroliranim sproščanjem
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
KR20010082251A (ko) 1998-10-26 2001-08-29 찌바따 이찌로, 다나까 도시오 서방성 입자
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
NZ513037A (en) * 1999-01-29 2003-05-30 Disphar Internat B Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
EP1064912B1 (de) 1999-07-02 2004-01-28 Cognis Iberia, S.L. Mikrokapseln - I
EP1207860B1 (en) 1999-09-02 2007-10-24 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
WO2001015665A1 (en) 1999-09-02 2001-03-08 Nostrum Pharmaceuticals, Inc. Controlled release oral dosage suitable for oral administration
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
EP1252887A4 (en) 2000-01-27 2009-07-29 Mitsubishi Tanabe Pharma Corp PREPARATION WITH EXTENDED RELEASE AND PROCESS FOR THEIR PREPARATION
CN1396829A (zh) 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
US6350471B1 (en) * 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
WO2002017883A2 (en) * 2000-08-31 2002-03-07 Rtp Pharma Inc. Milled particles
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
DE50113344D1 (de) * 2001-01-31 2008-01-17 Evonik Roehm Gmbh Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
PL202778B1 (pl) * 2001-02-22 2009-07-31 Skyepharma Canada Inc Postać dawkowana kombinacji statyny i fenofibratu, sposób jej wytwarzania i zastosowanie
AUPR752201A0 (en) * 2001-09-07 2001-09-27 Schefenacker Vision Systems Australia Pty Ltd Powered telescoping trailer tow mirror
ES2315425T3 (es) 2001-10-26 2009-04-01 PHARMACIA & UPJOHN COMPANY LLC Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos.
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
WO2004000280A1 (en) * 2002-04-29 2003-12-31 Shire Laboraties, Inc. Pharmaceutical formulations with improved bioavailability
US7588825B2 (en) * 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US6974820B2 (en) * 2002-11-06 2005-12-13 Bridge Pharma, Inc. Methods for treating urinary incontinence and other disorders using trospium
ES2645930T3 (es) * 2003-01-03 2017-12-11 Supernus Pharmaceuticals, Inc. Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
US20040138634A1 (en) 2003-01-10 2004-07-15 Litvay John D. Absorbent article having improved softness
JP2006515607A (ja) * 2003-01-22 2006-06-01 ファイザー・ヘルス・アクチエボラーグ 泌尿器障害を治療するためのトルテロジン及び他の抗ムスカリン様作用剤の用量の減少
US20040202693A1 (en) * 2003-04-14 2004-10-14 Rong-Kun Chang Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
EP1622450A4 (en) * 2003-04-25 2009-11-18 Endo Pharmaceuticals Solutions PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
US6772801B1 (en) 2003-05-14 2004-08-10 Shire Laboratories, Inc. Fluidization of particles for encapsulation in oral dosage pharmaceutical products
US7410978B2 (en) * 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
WO2006027783A2 (en) * 2004-09-08 2006-03-16 Ramot At Tel Aviv University Ltd. Mri imaging and contrast method
JP2006146117A (ja) * 2004-10-20 2006-06-08 Brother Ind Ltd 画像形成装置

Similar Documents

Publication Publication Date Title
JP2007510656A5 (enExample)
JP2012144577A5 (enExample)
ES2708955T3 (es) Formulaciones orales de deferasirox
US5814339A (en) Film coated tablet of paracetamol and domperidone
JP5911969B2 (ja) 心臓血管障害の治療方法
CA2653839A1 (en) Multiparticulate modified release composition
JP2011513391A (ja) ミコフェノラートを含有する徐放性医薬組成物およびその方法
TW201927304A (zh) 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
TW201006509A (en) Compositions comprising weakly basic drugs and controlled-release dosage forms
HUP0300698A2 (hu) N-acetil-p-aminofenol tartalmú készítmény
KR20150132399A (ko) 에베롤리무스를 포함하는 제약 조성물
WO2010128525A2 (en) A formulation of ivabradine for treating the cardiovascular disease
CA2537103A1 (en) Once daily dosage forms of trospium
JP2009517466A5 (enExample)
KR20100008356A (ko) 칼슘채널길항제를 포함하는 약제학적 제제
RU2014140177A (ru) Фармацевтические антиретровирусные композиции
AU2006275718B2 (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
US20070298098A1 (en) Controlled Release Compositions Comprising Levetiracetam
US20170100350A1 (en) Extended release compositions of an aminoalkyl nitrate
CA2505130C (en) Pharmaceutical compositions
WO2006088864A1 (en) Controlled release compositions comprising levetiracetam
JP6236079B2 (ja) ３種の活性成分を含有する新規な時差放出医薬組成物
JP2019532960A (ja) エソメプラゾール含有複合カプセル剤及びその製造方法
WO2009087690A2 (en) Multiparticulate extended release pharmaceutical composition of carbamazepine and process for manufacturing the same
JP2005510449A (ja) 改良型制御放出経口剤形